Resources
Access our latest resources—including publications about our science, recent media, and conference presentations.
Apr 2024 | From Ikena Oncology
IK-595, a best-in-class MEK-RAF molecular glue, drives broad and potent anti-tumor activity across RAS/MAPK pathway-altered cancers as a monotherapy and in combination
Eric Haines, Ph.D., M.Sc. | AACR Annual Meeting 2024
Oct 2023 | From Ikena Oncology
IK-595, a best-in-class MEK-RAF complex inhibitor, drives broad and potent anti-tumor activity in RAS/RAF-driven tumorsSource: From Ikena Oncology
Eric Haines, Ph.D., M.Sc. | EORTC-NCI-AACR 2023
Sep 2023 | From Ikena Oncology
IK-595 Targeting MEK-RAF Complex to Overcome CRAF Mediated Resistance & Drive Superior Anti-Tumor Activity in RAS/RAF Altered Cancers
Michelle Zhang, Ph.D. | 5th Annual RAS-Targeted Drug Development Summit 2023
Apr 2023 | From Ikena Oncology
IK-930, a Paralog Selective TEAD Inhibitor Effectively Attenuates Drug-Tolerant Persister Cell Proliferation
Daniel Hidalgo, Ph.D. & Marta Sanchez-Martin, Ph.D. | AACR Annual Meeting 2023
Apr 2023 | From Ikena Oncology
IK-930, a TEAD Paralog Selective Inhibitor for Treating YAP/TAZ-TEAD Dependent Cancers
Nathan Young, Ph.D. & Marta Sanchez-Martin, Ph.D. | AACR Annual Meeting 2023
Mar 2023 | From Ikena Oncology
IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers
X. Michelle Zhang, PhD | AACR Special Conference: Targeting RAS
Mar 2023 | From Ikena Oncology
IK-595, A MEK/RAF Complex Inhibitor, Obviates CRAF Mediated Resistance Resulting in Superior RAS/MAPK Pathway Inhibition and Anti-tumor Activity in RAS/RAF Altered Cancers
Eric Haines | AACR Special Conference: Targeting RAS
Mar 2023 | From Ikena Oncology
The Ah Receptor from Toxicity to Therapeutics. Report from the 5th AHR Meeting at Penn State University, USA, June 2022
McGovern, K et al. | International Journal of Molecular Sciences
Nov 2022 | From Ikena Oncology
A Phase 1b open-label, single-arm dose expansion study of IK-175, an oral AHR inhibitor, in combination with nivolumab in patients with primary PD-1 inhibitor resistant advanced head and neck cancer
Trupti Lingaraj | SITC 2022
Nov 2022 | From Ikena Oncology
Initial results from a Phase 1a/b study of IK-175, an oral AHR inhibitor, as a single agent and in combination with nivolumab in patients with advanced solid tumors and urothelial carcinoma
David H. Aggen, M.D., Ph.D. | SITC 2022
